ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Clinical Trial Participants Sue Duke University, Potti, Nevins and Others for Causing Harm

September 9, 2011

Shubik applauded for NCAB Service

February 12, 1982

Fischinger Names HHS AIDs Coordinator; DeVita Appoints Maryann Roper Acting Deputy Director

October 30, 1987

Chabner Says Some Group Satellites Causing Concern Because Of Lack Communications

March 4, 1983

Kennedy Chooses Health/Education Chair Over Judiciary; No Major Changes In Senate Cancer Policies Expected

November 14, 1986

Also in this 8-page issue: Rep. James Greenwood to become president of Biotechnology Industry Association.

July 30, 2004